Manipulation of Innate and Adaptive Immunity through Cancer Vaccines

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease

(2016) John Koreth et al.   BLOOD

Targeting neoantigens for cancer immunotherapy: Table 1.

(2016) Yong-Chen Lu et al.   INTERNATIONAL IMMUNOLOGY

Immunotherapy: Cancer vaccine triggers antiviral-type defences

(2016) Jolanda De Vries et al.   NATURE

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

(2016) Lena M. Kranz et al.   NATURE

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

(2016) Kelly D Moynihan et al.   NATURE MEDICINE

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses

(2016) Marij J. Welters et al.   Science Translational Medicine

Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

(2016) Michelle H. Nelson et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy Not Working? Check Your Microbiota

(2015) Nathan R. West et al.   CANCER CELL

Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma

(2015) C. D. Pham et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells

(2015) Charles J.M. Bell et al.   JOURNAL OF AUTOIMMUNITY

Dendritic-cell vaccines on the move

(2015) Rachel Lubong Sabado et al.   NATURE

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

Toward understanding and exploiting tumor heterogeneity

(2015) Ash A Alizadeh et al.   NATURE MEDICINE

Primed for a response

(2015) Sarah Seton-Rogers   NATURE REVIEWS DRUG DISCOVERY

Oncolytic viruses: a new class of immunotherapy drugs

(2015) Howard L. Kaufman et al.   NATURE REVIEWS DRUG DISCOVERY

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

(2015) J. Schuster et al.   NEURO-ONCOLOGY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Could microbial therapy boost cancer immunotherapy?

(2015) A. Snyder et al.   SCIENCE

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Oncogenic cancer/testis antigens: prime candidates for immunotherapy

(2015) Morten F. Gjerstorff et al.   Oncotarget

Tumor-Associated Macrophages in SHH Subgroup of Medulloblastomas

(2014) A. S. Margol et al.   CLINICAL CANCER RESEARCH

Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas

(2014) Ian F. Pollack et al.   JOURNAL OF CLINICAL ONCOLOGY

Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy Volunteers

(2014) Sawa Ito et al.   MOLECULAR THERAPY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

(2014) S. L. Highfill et al.   Science Translational Medicine

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

Cytomegalovirus and brain tumor

(2013) Charles S. Cobbs   CURRENT OPINION IN ONCOLOGY

Low-Dose Intradermal Infection with Trypanosoma congolense Leads to Expansion of Regulatory T Cells and Enhanced Susceptibility to Reinfection

(2013) Chukwunonso Onyilagha et al.   INFECTION AND IMMUNITY

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application

(2013) Taku Okazaki et al.   NATURE IMMUNOLOGY

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

(2012) Nadeem A. Sheikh et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The evolution of the danger theory

(2012) Polly Matzinger   Expert Review of Clinical Immunology

Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma

(2012) K. N. Kodumudi et al.   JOURNAL OF IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

(2012) S. A. Rosenberg   Science Translational Medicine

RNA-based vaccines

(2012) Jeffrey B. Ulmer et al.   VACCINE

Nucleic Acid Recognition by the Innate Immune System

(2011) Roman Barbalat et al.   Annual Review of Immunology

Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma

(2011) Xi Feng et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

An immune-active tumor microenvironment favors clinical response to ipilimumab

(2011) Rui-Ru Ji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cooperativity of adaptive and innate immunity: implications for cancer therapy

(2011) Anil Shanker et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Innate and adaptive immune responses to viral infection and vaccination

(2011) Taiki Aoshi et al.   Current Opinion in Virology

Dendritic Cell-Based Immunotherapy for Prostate Cancer

(2010) Hanka Jähnisch et al.   Clinical & Developmental Immunology

Immunotherapy Approaches for Malignant Glioma From 2007 to 2009

(2010) Laura A. Johnson et al.   Current Neurology and Neuroscience Reports

Intracellular Toll-like Receptors

(2010) Amanda L. Blasius et al.   IMMUNITY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

(2010) Mariola Fotin-Mleczek et al.   JOURNAL OF IMMUNOTHERAPY

Approval of Provenge Seen As First Step for Cancer Treatment Vaccines

(2010) V. Brower   JNCI-Journal of the National Cancer Institute

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer/testis (CT) antigens: Potential targets for immunotherapy

(2009) Otavia L. Caballero et al.   CANCER SCIENCE

Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68

(2009) Y. A. Yu et al.   MOLECULAR CANCER THERAPEUTICS

Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: Key regulators of innate immunity

(2009) Paola M. Barral et al.   PHARMACOLOGY & THERAPEUTICS

Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface

(2008) S. Vaishnava et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA